Ding Qian, Kong Xiangxu, Zhong Weilong, Liu Wentian
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Institute of Digestive Disease, Tianjin, China.
Front Oncol. 2022 Sep 2;12:971930. doi: 10.3389/fonc.2022.971930. eCollection 2022.
Colorectal cancer (CRC) is the third most common cancer in the world in terms of morbidity and mortality, which brings great health hazards and economic burdens to patients and society. A fecal examination is an effective method for clinical examination and the most commonly used method for the census. It is simple, non-invasive, and suitable for large-scale population screening. With the development of molecular biology, lots of efforts have been made to discover new fecal biomarkers for the early screening of colorectal cancer. In this review, we summarize and discuss the recent advances of fecal biomarkers for CRC screening or diagnosis, including DNA biomarkers, RNA biomarkers, protein biomarkers, gut microbes and volatile organic compounds focusing on their diagnostic evaluation for CRC, which can provide a basis for the further development of new and effective CRC fecal screening and early diagnosis techniques.
结直肠癌(CRC)在发病率和死亡率方面是世界上第三大常见癌症,给患者和社会带来了巨大的健康危害和经济负担。粪便检查是临床检查的一种有效方法,也是普查中最常用的方法。它简单、无创,适用于大规模人群筛查。随着分子生物学的发展,人们为发现用于结直肠癌早期筛查的新型粪便生物标志物付出了诸多努力。在本综述中,我们总结并讨论了用于CRC筛查或诊断的粪便生物标志物的最新进展,包括DNA生物标志物、RNA生物标志物、蛋白质生物标志物、肠道微生物和挥发性有机化合物,重点关注它们对CRC的诊断评估,这可为新型有效CRC粪便筛查和早期诊断技术的进一步发展提供依据。